Thu, Apr 17, 2014, 6:20 AM EDT - U.S. Markets open in 3 hrs 10 mins


% | $
Quotes you view appear here for quick access.

Qiagen NV Message Board

accurateinformation 8 posts  |  Last Activity: Apr 7, 2014 10:48 AM Member since: Oct 16, 2001
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • accurateinformation by accurateinformation Apr 7, 2014 10:48 AM Flag

    Roche Acquires POC MDx Firm Iquum
    April 07, 2014

    By a GenomeWeb staff reporter

    NEW YORK (GenomeWeb News) — Roche said today that it has acquired Iquum, a privately held company developing point-of-care molecular diagnostics.

    Under the terms of the agreement, Roche will pay IQuum shareholders $275 million upfront and up to $175 million in contingent product-related milestones. Once the transaction is complete, pending customary closing conditions, Marlborough, Mass.-based IQuum will be integrated into Roche Molecular Diagnostics.

    The acquisition provides Roche with access to Iquum's Liat (laboratory-in-a-tube) System, a point-of-care molecular testing system, as well as the Liat Influenza A/B assay, a rapid, near-patient test to detect and differentiate influenza A and B. Both the system and the assay have been CE marked and received 510(k) clearance from the US Food and Drug Administration.

    "With IQuum, we further strengthen our molecular diagnostics offerings with cutting-edge technology and products that serve the point-of-care segment," Roland Diggelmann, COO of Roche Diagnostics, said in a statement. "We welcome IQuum's employees, who will continue to focus on the development and manufacturing of the Liat Analyzer and assays."

    Last year, Iquum was named as one of three firms (along with BioFire Diagnostics, now part of BioMérieux; and Focus Diagnostics, a Quest Diagnostics subsidiary) to share more than $23 million from the US Department of Defense to develop a platform and assays to detect biological warfare agents.

  • Reply to

    Classic Head & Shoulders forming.

    by cepheid06 Feb 28, 2014 12:53 PM
    accurateinformation accurateinformation Feb 28, 2014 3:05 PM Flag

    So, it's dandruff time again?

  • accurateinformation accurateinformation Feb 21, 2014 9:13 AM Flag

    1. I have never said this stock was being manipulated. In fact, I challenge you to find any of my posts that say that.

    2. Drinking what? The company's koolaid? Hardly. They keep making outrageous claims about their things in R&D and their claims never come to fruition....EVER.

    Sentiment: Strong Sell

  • accurateinformation by accurateinformation Feb 20, 2014 9:57 PM Flag

    It is cyclic and occurs with disturbing regularity, like their "HIV cure", their Crohn's therapy", etc.

    Just big hat and no cattle...

    Sentiment: Sell

  • accurateinformation by accurateinformation Feb 12, 2014 1:46 PM Flag


    February 11, 2014

    A Kentucky state senator has introduced a bill aimed at so-called patent trolls that would criminalize making bad faith patent infringement allegations and making baseless demands for licensing fees, mirroring similar bills under consideration in Nebraska and Oregon.

    A draft of the bill released Monday by one of its co-authors, Republican state Sen. Whitney Westerfield, would enable the state attorney general to file legal action against entities that send out letters making vague or illegitimate patent-infringement litigation threats designed to intimidate their targets into licensing agreements....

    Sentiment: Strong Sell

  • accurateinformation accurateinformation Feb 10, 2014 7:07 AM Flag

    So, they are offing a test with fewer mutations and that isn't FDA cleared instead of the ILMN test with more mutations and that is FDA cleared?

    Sentiment: Strong Sell

  • Reply to

    SP Action/Reaction prior to CC

    by cepheid06 Jan 27, 2014 9:28 PM
    accurateinformation accurateinformation Jan 27, 2014 11:07 PM Flag

    It has NOTHING to do with the CC. It has EVERYTHING to do with what the competition has coming.

    QuantuMDx Eyeing 2015 Launch of Handheld POC MDx Device
    January 27, 2014

    By Tony Fong
    NEW YORK (GenomeWeb News) – After years in development, a handheld point-of-care molecular diagnostic device from QuantuMDx is poised to hit the market next year with malaria and tuberculosis as its initial target markets, a company executive said last week on the sidelines of the 32nd Annual JP Morgan Healthcare Conference in San Francisco.

    QuantuMDx has created a working prototype of the device, which is anticipated to be priced at around $500 and about the size of a cell phone. The company will be running trials internally through June and then it will beta test the device through the rest of 2014. If everything falls into place, the UK- based company will launch the instrument in 2015.

    While other firms such as Akonni Biosystems, Seegene, and Quidel are either developing or have developed handheld or point-of-care molecular diagnostic instruments, QuantuMDx's device will offer advantages in speed, portability, and price, the firm's Co-founder and CSO Jonathan O'Halloran told GenomeWeb Daily News.

    "We really wanted to reinvent the molecular diagnostic process … because we feel that if you are to do a real point-of-care molecular diagnostic device, it has to be portable," he said, adding that such a device must be able to provide results within 10 to 15 minutes, the amount of time a nurse of doctor spends with a patient, if it is to have use in a clinical setting.

    QuantuMDx's device works with a patient sample that is placed into a cassette, which is then placed into the reader, which analyzes the sample and delivers the results.

    The company had developed a benchtop instrument prior to the handheld device, but O'Hallaran said that the goal was always to develop an instrument that a clinician could carry around in a lab coat.

    Sentiment: Strong Sell

  • Reply to

    H1N1 back in town

    by dokdog Dec 28, 2013 11:10 AM
    accurateinformation accurateinformation Jan 17, 2014 5:03 PM Flag

    And so is the competition...

    Enigma Diagnostics CE marked it EnigmaML system and the company’s first FluAB-RSV diagnostic assay. The real-time PCR-based system is a raw sample-to-result instrument, which delivers results equivalent to central laboratory standards in up to 70 minutes, Enigma said. The assay detects all currently circulating influenza and RSV viruses from nasopharygeal swab samples.

    Sentiment: Strong Sell

20.34+0.33(+1.65%)Apr 16 4:00 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.